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The U.S. Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition (earlier referred to as the Bureau of Foods) has recommended the inclusion of an in utero exposure phase when asses sing the ca r cinogenicity potential of ce r tain f ood a dditives f or over 20 years . In 1970 the FDA hosted an Advisory Panel of Protocol Evaluation for Cancer Tes ting in the Safety Evaluation of Food Additives and Pes ticides. One of the recommendations made by the advisory committee on cancer tes ting stated, ªIdeally carcinogenesis tes ts s hould be begun prior to conception and be continued in the offspringº (U.S. FDA, 1971) . During the U.S. FDA Expert Advisory Committee's cons ideration of the need to combine chronic toxicity and repr oduction s tudies , it referr ed to the w ork of s elected author s (Ivanokovitch et al., 1966; Druckrey, 1973) and noted that tumors could be produced late in the life of animals after administration of a carcinogen during pregnancy of the mother. These experimental results indicated that the embryo and fetus might sometimes be particularly vulnerable targets for carcinogenic substances (U.S. FDA, 1971 ).
In the expert committee's view, thes e ® ndings s uggested the need to modify certain aspects of the protocols typically us ed for chronic toxicity studies . Thus, the expert committee concluded that the combination of the ® rs t s tages of the reproduction s tudy with the chronic toxicity study would provide certain advantages and might prove to be an adequate test for carcinogenic hazard (U.S. FDA, 1971 ).
EARLIER STUDIES ON PERINATAL CARCINOGENESIS
Two early studies of the influence of transplacental exposure to carcinogens (Larsen, 1947; Smith & Rous, 1948) reported that the administration of urethane to pregnant female mice accelerated the rate of developm ent and number of lung tumors in their offs pr ing. Lars en (1947) reported that the intraperitoneal injection of pregnant Strain A fem ale mice at tim e intervals ranging fr om 1 to 5 days prepartum r es ulted in an s tatis tically s ign if ican t incr eas ed inciden ce of lu ng tumors compared with postpartum exposure beginning at adolescence. A clear trend suggested that the pregnant dams injected nearest to term produced offspring that manifested the greates t elevation in tumor incidence and average number of tumors per lung (Lars en, 1947) .
Am ong inf luen tial inves tiga tors us ing the n eona tal a nd inf an t a nim als as s en s itive s ys tem s in car cinogenicity as s es s m en t w ere Pietra and ass ociates (Pietra et al., 1959 (Pietra et al., , 1961 . In a study by Pietra et al. ( 1961) , the adm inis tration of s ingle dos es of 7 ,12-dime thylbenz[a]anthrace ne, benzo[a]pyrene, 3-m ethylcholanthrene, and urethane to newborn Swiss mice resulted in an increased incidence of, earlier appearance of, and less differentiated type of malignant lymphomas than controls.
ROLE OF AGE AND DURATION OF TREATMENT ON CARCINOGENESIS
When ethylnitros ourea (ENU) was administered intraperitoneally to (C57BL/6J 2 C3HeB/FeJ ) F1 mice during prenatal or postnatal periods, distinct differences were seen in the site of tumor occurrence. Sixty micrograms of ENU per gram body weight was administered on day 12, 14, 16, or 18 of intrauterine life or on day 1, 15, or 42 pos tpartum. The mice were maintained and observed for tumors during their lifetime. In general, the animals treated with prenatal exposure demons trated a narrower tumor spectrum than anim als treated pos tnatally. Fetus es treated transplacentally with ENU developed 15 primary tumors in lungs, liver, kidneys, central nervous system, stomach, and ovaries. In thos e m ice rece iving ENU pos tna tally, 59 pr im a ry tum or s w er e obs erved in 22 tissues (Ves selinovitch et al., 1979) . These authors then compared s ensitivity to expression of carcinogenicity in various tissues of mice given benzo[a]pyre ne (B aP), dim ethylnitros am ine (DMN) , diethylnitrosamine (DEN), benzidine (BZ), and a¯atoxin B1 (AFB) at different postpartum ages. ENU mediated carcinogenesis at 22 tissue sites , BaP at 9 organ sites, DEN at 2 organ s ites, and BZ at 1 organ site. At a dose of 1.5 (µ g/g body weight, fewer tumors were observed in mice treated at age 1 day than in animals treated at 15 days. Thes e results led the primary investigators to conclude that infant rather than fetal animals were most susceptible to carcinogenesis, as shown by a range of tiss ues that responded to thes e particular carcinogenic agents (Vesselinovitch et al., 1979) .
In a subsequent study, Vesselinovitch (1983) reported that the rates of hepatocarcinogenes is m ediated by prenatal, preweaning, or adult exposure of B6C3F1 mice to benzidine, safrole, amitrol, and ENU were as sessed. Only ENU demonstrated prenatal carcinogenicity as it does not require enzymatic activation. Infant mice have both enzymatic activation and high rates of macromolecular replication, as emphasized by the elevated neoplastic respons e measured in the cas e of benzidine, safrole, amitrol, and ENU following pos tpartum adminis tra tion. Adult mice dis played a decreased susceptibility to ENU compared with the response of infant animals. This may indicate a comparative lack of or lower rate of macromolecular replication in mice of this age. Thus, perinatal expos ure to these agents was more hepatocarcinogenic than s imilar adult exposure. With this set of test materials, however, the infants were generally shown to be more res ponsive to tumor formation than fetuses (Vess elinovitch, 1983).
COMPARISON OF PERINATAL AND ADULT CHEMICAL EXPOSURE ON TUMOR EXPRESSION
A large survey of the carcinogenicity literature was recently published (McConnell, 1992) . Mos t of thes e s tudies were not speci® cally designed to compare the influence of perinatal (i.e., pre-and early postnatal) chem ica l expos ur e w ith s ta ndar d car cinogenes is bioas s ay expos ure (pos tnatal) on tumor incidence mediated by individual substances , so the review concentrated on ca rcinogenicity s tudies that at leas t included a perinatal exposure component.
A summary of test results modi® ed from a report compiled by the U.S. Environmental Protection Agency (U.S. EPA, 1996) on the comparison of the effects of chemicals with combined perinatal and adult exposure versus adult-only exposure in carcinogenesis assays is provided below. Table 1 indicates that in a qualitative sense, perinatal expos ure typically reveals the same type of tumors that the standard carcinogenicity bioassay does. It is also true, however, that neonatal exposure combined with continuing exposure to the test substance throughout the lifetime of the experimental subjects results in a higher incidence of tumors and the latency to tumor occurrence appears to be decreased. Table 1 demonstrates that tumors are found with increased incidence or at additional organ sites during adult exposure to a¯atoxin B1, anethole, estragole, DDT, and safrole when compared with mice exposed to the s ame compound during the perinatal period. Convers ely, tumors appeared with higher incidence or at additional organ s ites during perinatal plus adult exposure compared to adult-only exposure with diethylnitros am ine (DEN ora l), dieldr in, ethylenethiour ea (ETU), injected ethylnitrosurea (ENU), and diethylstilbestrol (DES). The increased incidence of tumors resulting from exposure to two compounds, eugenol and s acch arin, w as more reliably detected with combined perinatal and adult exposure than with adult expos ure alone. One food additive, saccharin, was only found clearly carcinogenic when it was administered during the early postnatal period. There is at leas t one report in the literature, how ever, that indicates a marginally increased incidence of bladder tumors in male rats when saccharin is given to adults (Arnold et al., 1980) . This analysis of the in¯uence of perinatal exposure by the U.S. Environmental Protection Agency als o included a review of unpublis hed studies on the potential carcinogenicity of certain food additives in the ® les of the U.S. Food and Drug Administration's Center for Food Safety and Applied Nutrition. The substances tested included several classes of food additive substances including (1) s weeteners such as acesulfampotassium;
(2) colors such as FD&C blue no.2, yellow nos. 5 and 6, and red no. 40; (3) bulking agents s uch as modi® ed polydextros e and gellan gum; and miscellaneous agents such as s odium nitrite, fumaric acid, acetylated monoglycerides , 3-hydroxy-4-pyrone, and caramel.
In these chronic carcinogenicity studies , both parental animals (rats typically) are treated prior to and at mating. Treatment of the dams continues through gestation and lactation. The dams are s acri® ced at weaning of the offs pring and the offs pring are then exposed continuously to the tes t material to approximately 2 yr of age. This is the normal test design recommended by the FDA for as sessing carcinogenicity potential for high-expos ure food additives . While it is clear that there is some bias of ascertainment with these studies (compounds revealed to be carcinogenic in thes e types of studies would not typically be submitted to the FDA), no carcinogenic res ponse was found for 12 of 13 of these food additives . Only s odiu m nitrite s how ed a m ar ginal incr eas e in tumors of the spleen of treated rats in both the standard bioas say and with the carcinogenesis s tudy that included a perinatal exposure phase (unpublished studies from U.S. FDA ® les).
SPECIALLY DESIGNED COMPARATIVE STUDIES
The National Institute of Environmental Health Sciences recently conducted a series of s ix studies that were designed to speci® cally examine the com par ative influence of perina tal and adult expos ure to thr ee kn own anim al car cinogens : 5,5 -diphenylhyda ntoin (DPH), e th ylenethiourea (ETU), and polybrominated biphenyls (PBB). These three chemicals were administered to rats and mice in varying concentrations in the diet; DPH, 0± 2400 ppm ( ra ts ) a nd 0± 6 00 ppm (m ice ) ; ETU, 0± 250 ppm (rats) and 0± 1000 ppm (mice); PBB, 0± 30 ppm (rats and mice). Each of these s tudies was designed to determine whether perinatal exposure added to adult, long-term exposure might increase the qualitative and quantitative sensitivity of the carcinogenicity as sessment of these chemicals. Speci® cally, in each of these s tudies there was one group of animals in which the maternal animals were exposed to the test material before breeding, through gestation, during lactation and weaning, and then through dietary exposure of offspring to the age of 8 wk (perinatal expos ure) followed by control diet for 2 yr. A s econd group of animals was expos ed to the test material for 2 yr beginning at 8 wk. The third set of animals was expos ed perinatally up to 8 wk and then continued administration in the diet for 2 yr (Chhabra et al., 1991 (Chhabra et al., , 1993a (Chhabra et al., , 1993b .
In two studies with ETU, perinatal exposure alone caused no carcinogenic effects in either rats or mice. Adult administration did res ult in enhanced express ion of thyroid follicular cell tumors in rats and mice and hepatocellular and pituitary tumors in mice. Combined perinatal and adult expos ure to ETU replicated the observations in adult-only exposure with a s lightly increased incidence of thyroid follicular cell tumors in rats. Generally speaking, the tumorigenic effects of ETU were not affected by the inclusion of perinatal administration into the traditional adult bioassay in rats and mice (Chhabra et al., 1991) .
In those studies utilizing DPH as the test material, perinatal-only exposure did not increas e tumor incidences at any sites in the rats, but it did produce a small increase in the incidence of hepatocellular tumors in female mice. Adult-only administration of DPH resulted in increases in hepatocellular tumors in female mice and a marginal increase (statistically nonsigni® cant) in this tumor in male rats. Combined perinatal Indirectly acting agents (this dichotomous clas si® cation is less accepted than previously). and adult expos ure induce d an increas e in hepatocellular tumors in male rats and in male and female mice. Moreover, the combined perina tal and adult expos ure produce d an incr eas e in the inciden ce of hepatocellular tumors in male mice that was not observed in adult-only exposure (Chhabra et al., 1993a) . The ® nal series of studies was conducted with PBB. Perinatal-only administration marginally increas ed the incidence of hepatoce llular tumors in male rats only, while in mice perinatal-only exposure produced hepatocellular tumors in both s exes. Adult-only exposure mediated hepatocellular tumors in both sexes of rats and mice. The combined adult and perinatal exposure replicated the increased hepatocellular tumor rate in rats and mice. The results also demonstrated that combined perinatal and adult adm inis tr ation increa s ed PBB-media ted hepatocellular tumors in comparis on to the adult-only expos ure. An increased incidence of leukemia was observed in both male and female rats in perinatal-only expos ure, adult-only expos ure a nd com bined types of exposure to PBB (Chhabra et al., 1993b) .
An overall analysis of results from these three studies suggests that (1) perinatal exposure alone does not consistently increase the incidence of tumors; (2) similar types of tumors in similar tissues were observed with perinatal-only and adult-only exposures; and (3) combined perinatal and adult exposure resulted in a higher tumor incidence compared to that of either of the other exposure designs .
DISCUSSION OF RESULTS AND REGULATORY TESTING RECOMMENDATIONS
The results of these studies suggest certain conclusions. Whether the incidence of tumors resulting from perinatal-only or adult-only expos ur e ca n be elevated com pa red with com bined perinata l and adult expos ure depends on the compounds tes ted. Aflatoxin B1, anethole, es tragole, DDT, and s afrole all produced higher tumor incidences in mice with the adult-only exposure (McConnell, 1992) . Conversely, DEN, dieldrin, ETU, ENU, and DES mediated higher tumor incidences when perinatal expos ure was included (McConnell, 1992) . McConnell (1992) r epor ted th at eugenol an d s acch ar in w ere only tu morigen ic w hen administered during the perinatal period. Some studies indicated that the occurrence of tumors was quite similar or the same in res ponse to a given carcinogen, regardless of the timing of compound expos ure; however, experimental designs that included perinatal expos ure along with adult exposure commonly produced a higher incidence of tumors and in s om e cas es , a s horte r la tency to tum or ons et ( McConnell, 199 2 ; Chhabra, 1991 Chhabra, , 1993a Chhabra, , 1993b .
Accumulation of suf® cient test data and re® nement of information relating to structure± activity relationships may allow investigators to one day use results from these types of studies to unders tand and even predict s om e of the general ca rcinogenic res pons es relating to tim e and duration of exposure to a given material that is to be tes ted. For example, becaus e ENU doe s not require metabolic con version to an active form, it can be a potent tumorigen in these animals who do not have enzyme metabolizing capability but do poss ess rapidly developing tiss ues with rapid rates of macromolecular turnover (Ves selinovitch, 1983) . The presence of rapid macromolecular replication may hint why eugenol and s accharin elicit tumors when they are administered during fetal development and/or very early postnatal life, respectively (Vesselinovitch, 1983; Miller et al., 1983; Schoenig et al., 1985) .
Neither our unders tanding of s tructure± activity relations hips for metabolic conversions nor our knowledge of carcinogenic mechanisms has progressed far enough for the Center for Food Safety and Applied Nutrition (CFSAN) to predict with a suitable degree of certainty those s ubstances that do not need early perinatal or in utero expos ure to as certain their carcinogenic potential. This statement is based on the author 's firs thand experience with the very broad range of chemical s tructures regulated and the quite limited amount of data normally available on the comparative metabolism and mechanism(s) mediating the carcinogenic res pons e(s). The author sugges ts that the database that we have available to gain comparative insight into the effects of food additives and therefore the need for in utero testing is quite limited. Perhaps with the accumulation of additional carcinogenicity testing data, toxicologists will eventually posses s the tools to decide with gr eater con fidence w hen in utero tes ting is unnece s s a ry. While the author cons iders that a more detailed discuss ion of carcinogenic mechanisms to be beyond the s cope of this article, those readers wishing a more mechanistic cons ideration of how age and other treatment conditions may in¯uence the express ion of carcinogenesis in animal models may consult these reviews (International Agency for Research on Cancer, 1983 Cancer, , 1985 Cancer, , 1989 .
It is clear from the preceding discus sion that certain carcinogenic substances , such as eugenol and saccharin, expres s their carcinogenic potential only when administered in the perinatal period. Moreover, certain other subs tances , such as DEN, dieldrin, ETU, ENU, and DES, express their full carcinogenic potency only when both adult and perinatal exposure are included in the s tudy des ign.
An additional factor that the FDA must weigh in its consideration of the appropriate role for in utero tes ting of food additives in animal models is that unlike many other regulated products, there is an ªauto-maticº and continuous exposure to many food additives. Thus, all segments of the human population (regardles s of their respective con ditions) can be exposed to food additives on a continuous and unwitting basis. This places a greater burden and responsibility on this Center in terms of assuring the safety of food additives in certain groups like pregnant women and their offspring. Thus, the con fluence of several circums tance s Ð unce rtainty in s tructure± activity analys is , the la ck of important data relating to metabolism and carcinogenic mechanis m, and the exposure of all age groups , including pregnant women, to food additives Ð underscores the CFSAN recommendation that carcinogenicity tes ting for high-expos ure food additives include an in utero phase.
For the pres ent, however, the FDA Center for Food Safety is reexamining its basis for recommendations regarding an in utero phase for carcinogenicity testing.
With the original vers ion of the To x i c o l o g i c a l P r i nc i p l e s f o r t h e S a f e t y A s s e s s m e n t o f D i r e c t F o o d A d d i t i v e s a n d C o l o r A d d i t i v e s U s e d i n F o o d
(often referred to as the Redbook), the FDA recommended an in utero testing phase for either a s ubchronic or chronic (length of study re¯ects the level of exposure and thus intens ity of toxicological tes ting needed for a given compound) feeding study. The conditions necessary to elicit the in utero recommendation were: (1) compounds that had a lowest ªeffectº dose level of less than 200 times the human expos ure; (2) compounds that were nonnutritive additives with an exposure exceeding 0.25 mg/kg/day in the diet; (3) compounds that were nutritive additives; (4) compounds with reproductive toxicity or teratogenic activity; and (5) compounds with data indicating differences in affected organ in in utero versus non± in utero s tudies . During its reassess ment of the s election decis ion elements for the current revision of the Redbook, these qualifying recommendations for including the in uter o ph as e dur ing ca rcin ogen icity tes ting a re being car efully reassess ed.
